Latest market price
70.11
-11.44-14.03%
TXGQT6810x Genomics, Inc.·NASDAQ
70.11-14.03%
News
Down 14.0% — Single-Cell eQTL Clinical Workflows Market Forecast to Reach $4.51 Billion by 2030 | Capitalize on 19.9% CAGR with Illumina, QIAGEN, 10x Genomics, Singleron and More (Yahoo).
Medium confidence
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E—EPS (ttm)-0.59Insider Own7.18%Shs Outstand130.29MPerf Week-2.01%
Market Cap9.13BForward P/E—EPS next Y-0.72Insider Trans-2.97%Shs Float116.15MPerf Month-21.01%
Enterprise Value8.66BPEG—EPS next Q-0.27Short Float10.96%Perf Quarter49.14%
Income-74.00MP/S14.81EPS this Y—Short Ratio3.83Perf Half Y212.57%
Sales617.00MP/B11.06EPS next Y—ROA-7.29%Short Interest12.73MPerf YTD329.86%
Book/sh6.34P/C16.55EPS next 5Y—ROE-9.33%52W High102.82 -31.81%Perf Year443.49%
Cash/sh4.24P/FCF74.87EPS past 3/5Y—ROIC-9.57%52W Low12.34 468.15%Perf 3Y89.38%
Dividend Est.—EV/EBITDA—Sales past 3/5Y7.61% 16.55%Gross Margin70.03%Volatility8.49% 9.06%Perf 5Y-57.26%
Dividend TTM—EV/Sales14.04EPS Y/Y TTM—Oper. Margin-14.33%ATR (14)6.92Perf 10Y—
Dividend Ex-Date—Quick Ratio5.25Sales Y/Y TTM-4.34%Profit Margin-12.18%RSI (14)44.49Recom2.59
Dividend Gr. 3/5Y—Current Ratio5.69EPS Q/Q-150.00%SMA20-7.71%Beta2.01Target Price83.30
Payout0.00%Debt/Eq0.10Sales Q/Q-12.72%SMA50-5.47%Rel Volume1.52Prev Close81.55
Employees1,178LT Debt/Eq0.08EarningsNov 05SMA20072.80%Avg Volume3.41MPrice70.11
IPO DateSep 12, 2019Option/ShortYes / YesEPS/Sales Surpr.42.41% 2.97%Net Debt/EBITDA-12.45Volume5,184,453Change-14.03%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-13-26ReiteratedStifel Nicolaus$50 → $70
Oct-12-26ReiteratedCanaccord GenuityBuy$60 → $100
Oct-07-26ReiteratedBarclaysOverweight$40 → $110
Sep-29-26ReiteratedLeerink PartnersMarket Perform$40 → $90
Sep-28-26InitiatedArgusBuy$110
Sep-28-26ReiteratedPiper SandlerNeutral$47 → $80
Sep-09-26ReiteratedUBSNeutral$20 → $68
Sep-01-26ReiteratedRBC Capital$70
Aug-12-26ReiteratedStephens & Co.Overweight$65
Aug-10-26ReiteratedPiper SandlerNeutral$47
Latest News· Times ET
Oct-30-26
Oct-29-26
Oct-27-26
Oct-23-26
Oct-17-26
Oct-16-26
Oct-13-26
Oct-12-26
Oct-09-26
Oct-08-26
Oct-07-26
Oct-05-26
Oct-04-26
Sep-30-26
Sep-29-26
Company

Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue617643611619—————
Cost of Goods Sold Incl. D&A186199196209—————
Gross Profit431444414409—————
Selling, General and Administrative Excl. Other297316344343—————
Research and Development227239265270—————
Other Operating Expense-30062—————
Operating Income-89-111-195-265—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)13711717—————
Net Income Before Taxes-75-40-178-249—————
Income Taxes0456—————
Consolidated Net Income-74-44-183-255—————
Net Income From Continuing Operations-74-44-183-255—————
Net Income-74-44-183-255—————
EPS (Recurring)-0.59-0.35-1.52-2.18—————
EPS (Basic, Before Extraordinaries)-0.59-0.35-1.52-2.18—————
EPS (Diluted)-0.59-0.35-1.52-2.18—————
EBITDA384-134-205—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio14.773.172.8210.58—————
Gross Margin69.8569.0567.7666.07—————
Operating Margin-14.42-17.26-31.91-42.81—————
Net Margin-11.99-6.84-29.95-41.20—————
Shares Outstanding130125120117—————
Market Capitalization9,1142,0391,7236,547—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$110.70$82.62$54.54$26.46$-1.62● Close Price0.00M1.68M3.36M5.04M6.73MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
SULIMAN SHEHNAAZDirectorSep 22 '26Sale81.195,723464,66823,792Sep 24
Saxonov SergeChief Executive OfficerSep 22 '26Sale81.2225,0002,030,5611,050,249Sep 24
Taich AdamChief Financial OfficerSep 09 '26Sale64.5746,3882,995,470316,344Sep 11
STUELPNAGEL JOHN RDirectorSep 03 '26Sale61.7520,0001,235,071328,436Sep 08
Saxonov SergeChief Executive OfficerAug 26 '26Sale63.6910,486667,9001,075,349Aug 28
Saxonov SergeChief Executive OfficerAug 24 '26Sale63.0218,5451,168,7751,085,835Aug 26
Taich AdamChief Financial OfficerAug 24 '26Sale63.0217,1661,081,853362,732Aug 26
Hindson Benjamin J.Director, OfficerAug 24 '26Sale63.0213,818870,860488,182Aug 26
SULIMAN SHEHNAAZDirectorAug 24 '26Sale63.652,207140,47829,515Aug 26
Teichmann Sarah A.DirectorAug 14 '26Sale57.152,273129,90228,058Aug 17
Teichmann Sarah A.DirectorAug 13 '26Sale57.295,278302,37730,331Aug 17
STUELPNAGEL JOHN RDirectorAug 11 '26Sale57.7520,0001,155,055348,436Aug 13
Saxonov SergeChief Executive OfficerJun 22 '26Sale34.4430,0001,033,2671,108,380Jun 24
SULIMAN SHEHNAAZDirectorJun 16 '26Sale32.635,723186,75631,722Jun 18
Saxonov SergeChief Executive OfficerMay 26 '26Sale24.7110,718264,8331,138,380May 27
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.